Madrigal’s former clinical development head files whistleblower lawsuit alleging Rezdiffra safety cover-up

Madrigal Pharmaceuticals is facing a whistleblower lawsuit alleging that senior leadership censored serious liver-injury data related to its breakthrough MASH drug Rezdiffra and retaliated against the firm’s top clinical development head who tried to sound the alarm.